Methodology
How the Briefing knows what it says
Three things make this site more than a collection of articles: an evidence class on every claim, a recorded source behind every material fact, and an explicit graph connecting everything to everything else.
01 · Evidence
Eleven labels, six kinds of claim
The mark beside each label is drawn more or less solidly according to how established the claim is: solid for established, outlined for reported, dashed for projected.
- Peer reviewedFact
- Published in a journal after independent expert review. The strongest routine form of scientific evidence, though single studies still need replication.
- PreprintReported claim
- A full manuscript shared publicly before peer review. Methods are open to scrutiny, but conclusions may change.
- Clinical registryFact
- Taken from a public trial registry such as ClinicalTrials.gov. Reliable for what a study is and its status; says nothing by itself about results.
- Regulatory sourceFact
- A decision or designation by a regulator. Read the scope carefully: a designation or a limited clearance is not an approval for general use.
- Company reportedReported claim
- Stated by the company itself in a release, blog post or presentation. Not independently verified and usually without full methods.
- Independent reportingIndependent verification
- Reported by a news organisation or trade publication independent of the subject.
- Open-source repositoryFact
- Read directly from the project's public repository metadata on the retrieval date shown.
- Dataset sourceFact
- Taken from the dataset's own documentation or hosting repository.
- Organiser's announcementReported claim
- Stated by the organiser of an event on its official page: dates, place, deadlines. Reliable for what is planned. Plans change, so each entry carries the day the page was last read.
- BCI Briefing analysisInterpretation
- Our editorial interpretation of the evidence. Reasoned, but a judgement rather than a finding.
- EstimateEstimate
- An approximate figure derived from incomplete public information.
- ForecastForecast
- A forward-looking statement. Uncertain by nature and never to be read as fact.
02 · Provenance
Every source, and how far it was checked
Each source records its type, publisher, publication date, retrieval date and a verification state. The corpus was assembled on 3 Oct 2026; the sources for the coverage of China, Europe, Japan and South Korea were read on 4 Oct 2026.
- 203
- Checked against source
- Opened and read against the claim: PubMed records, registry entries, repository metadata and news articles.
- 20
- Source identified, not opened
- Found through search or secondary reporting; the primary document was not opened.
- 4
- Awaiting source check
- Recorded from editorial knowledge of the public record. Flagged wherever it appears.
- 1
- Editorial / illustrative
- Our own analysis and forecasts. Never presented as fact.
Papers are checked against their PubMed record and quoted only from the published abstract. Clinical studies are transcribed from the ClinicalTrials.gov API. Tool metadata is read from the GitHub API and shown as dated fact, never converted into a score.
Where a figure could not be traced to a source, it is not shown. Qualitative views — the frontier zones, the momentum field, the open-frontier dimensions, the technology ranges — are editorial judgements and are labelled as BCI Briefing analysis.
03 · The graph
A map, not a feed
386 entities, 1140 typed relationships. A paper links to its trial, its dataset and the companies building on it, which is why you can arrive for one thing and find the next.
Entities
- Investor54
- Institution46
- Company40
- Paper34
- Technology32
- Clinical study27
- Tool23
- Device20
- Funding round20
- Regulatory event17
- Researcher16
- Event13
- Dataset10
- Frontier10
- Use case9
- Briefing8
- Standard4
- Dossier3
Relationships
- TARGETS195
- USES149
- ADVANCES125
- SUPPORTS104
- REFERENCES93
- AFFILIATED_WITH90
- PARTICIPATED_IN69
- CONCERNS60
- HOSTS46
- AUTHORS41
- TESTS22
- BUILDS21
- RAISED20
- SPONSORS18
- REPORTS_ON17
- ANALYZES16
- EVALUATES12
- IMPLEMENTS12
- COVERS11
- CONTAINS10
- FOCUSES_ON7
- ORGANIZES2
04 · Vocabulary
Categories we never blur
Clinical stage
- Preclinical
- Bench, animal or cadaver work. No human participants.
- First-in-human
- The first use of a device in a small number of people, focused on safety.
- Feasibility
- Small early studies that test safety and whether the device can do what it is meant to.
- Clinical study
- A larger structured study of safety and performance, short of a pivotal trial.
- Pivotal
- The trial designed to support a marketing application.
- Approved / cleared
- Authorised by a regulator for a defined use. Always check the scope.
Access today
- Available
- Authorised and obtainable for a defined group of patients or users.
- Clinical study
- Accessible only by enrolling in a registered clinical study.
- Experimental human research
- Demonstrated in a small number of research participants. Not an established treatment.
- Preclinical
- Not yet tested in people.
- Concept
- A proposed approach without published human or animal demonstration.
- Forecast
- A possibility, not a product or a result.
Frontier zones
- Demonstrated today
- Shown in people and reproduced across participants or groups, or authorised for use.
- Early clinical
- First human evidence: individual participants or small early studies.
- Research frontier
- Active research with partial or preliminary human evidence.
- Emerging possibility
- Plausible directions without convincing human evidence yet.
05 · Scope
What we count as BCI
Broad enough to follow the field as it converges with neuromodulation and wearable interfaces. Explicit enough that a wrist band and a speech implant are never presented as the same thing.
Every organisation carries one primary class, shown on its profile, and may carry further ones where its work spans several. Only the primary class decides what it is counted as. An organisation is counted as a BCI company when that class is core or bidirectional BCI; everything else belongs to the wider neural-interface landscape. Not every neurological device company is a BCI company, and we do not list one as such because it would make the field look larger.
- Core BCIThe centre of our coverage · 19 profiled
Records activity from the brain and decodes it into a command, text, speech or movement for the person it is recorded from.
For example: Intracortical, ECoG, endovascular and EEG systems for communication, cursor control or movement.
- Bidirectional BCIThe centre of our coverage · 1 profiled
Reads from the brain and writes back to the nervous system in the same system, with the reading shaping the stimulation.
For example: Decoded movement with sensory feedback by cortical microstimulation; a brain–spine interface.
- Neural interfaceCovered where it meets BCI · 8 profiled
Hardware that records from or stimulates the brain and is being developed toward BCI use, without a demonstrated closed decoding application yet.
For example: Electrode arrays, implant platforms and ultrasound interfaces at preclinical or early human stage.
- NeuroprostheticCovered where it meets BCI · 3 profiled
Replaces a lost sensory or motor function by stimulating the nervous system, without decoding the user's intent from the brain.
For example: Retinal and cortical visual prostheses, cochlear and auditory brainstem implants.
- NeuromodulationCovered where it meets BCI · 5 profiled
Stimulates the nervous system to treat a condition. Systems that sense neural activity and adapt to it (closed loop) are where the class meets BCI. Open-loop systems are profiled only where they bear on the field, and are never counted as BCI.
For example: Responsive neurostimulation for epilepsy, adaptive deep brain stimulation, closed-loop stimulation for depression or stroke recovery.
- Peripheral / neuromotor interfaceCovered where it meets BCI · 2 profiled
Reads intent outside the brain, from muscle or peripheral nerve, and uses it to control a device.
For example: Wrist sEMG bands, myoelectric prosthetic hands, nerve-cuff interfaces.
- Bioelectronic medicineContext only · 1 profiled
Interfaces with a peripheral nerve, most often the vagus nerve, to treat disease in an organ system. Nothing is decoded from the brain and no sense or movement is restored.
For example: Selective vagus nerve stimulation for hypertension, heart failure or inflammation.
- BiohybridContext only · 0 profiled
Couples electronics with living neural tissue that is grown or kept outside a body. Related science, not an interface with a person.
For example: Cultured neurons on electrode arrays used for computing or drug testing; organoid interfaces.
- Enabling technologyCovered where it meets BCI · 0 profiled
Makes the instruments, components or platforms that BCI research and products are built with, where that is the organisation's main business.
For example: Biosignal amplifiers and real-time processing environments, electrode and implant manufacturing, surgical robotics for implantation.
- Adjacent technologyContext only · 1 profiled
Surrounds the field without being an interface to the nervous system for control or restoration.
For example: Open-loop stimulators, neuroimaging analytics, consumer wellness headbands without a control function.
06 · Trends and geography
Counting change, and saying where the count stops
Trend figures come from collectors that read public sources on a schedule: PubMed and OpenAlex for research, ClinicalTrials.gov for studies, GitHub for tools. What they find is stored as retrieved, deduplicated on stable identifiers, classified by published keyword rules and only then counted. Company facts, funding and regulatory actions are entered by editors from cited documents.
Each chart is drawn from a dated snapshot that is never altered afterwards. A trajectory compares growth over the latest three complete years with the three before; the year in progress is shown and not read. Samples, such as our list of funding rounds, are shown as levels only.
Geography is recorded for every company, study, paper and round. An internal audit compares what we hold for each region with that region’s share of the world’s publications and flags where we look thin. Sources in other languages are cited with their original title and a translation, marked as checked or unchecked.
07 · Patents
A reading of filings, not of rights
The BCI Briefing provides technical and editorial information about patents. It does not give legal advice, an opinion on the scope or validity of any patent, or a freedom-to-operate analysis.
Source. Patent data comes from the European Patent Office’s Open Patent Services, which serves its worldwide bibliographic database and its database of events recorded by patent offices. Records are read through that service only. Espacenet is linked from every family so that a reader can check the record, its claims and its description; it is never read by a program.
Discovery. The world’s patents are not crawled. Three kinds of narrow search are run, and they overlap on purpose: everything filed by 26 organisations the site profiles; the classification groups that are about the field by definition (computer input from nervous-system activity, invasive electrodes for brain recording, brain cortex electrodes); and the field’s wording together with the wording of its hardware, such as packaging, telemetry or insertion with a neural subject. Recall comes from the overlap.
Who filed. A name in a register is not an identity. Each organisation is searched under the names offices hold for it, including transliterations and earlier names, and a family is linked to it only when the applicant’s name matches a pattern that was checked by hand. 8 organisations are deliberately not searched by name, among them Merge Labs and Araya, because records under their name belong to someone else, or because their portfolios are almost entirely outside the field. Applicants are shown as recorded; an applicant is not always the present owner.
What is counted. Every family found passes the same published rules, whichever search found it. Independent signals add up: the field named in the title or abstract, a class that is about the field, a neural subject together with a part of the stack, a profiled applicant, a citation of a counted family. A family is counted when they agree. Neural technology that is plainly something else, such as a stimulator that reads nothing, a hearing implant or a sleep monitor, is kept as adjacent and not counted. What the rules cannot settle is left uncounted, and goes to an editor where it belongs to a profiled organisation. Of the families held now, 7,312 are counted, 951 are adjacent and 901 are uncertain.
The unit. One invention is published many times: as an application and as a grant, in several offices. All of those are one family, and a family is counted once, in the year of its earliest priority, which is when it was first filed anywhere. Publication counts are never used as a measure.
Layers and themes. A family is placed in the 11 layers and 24 themes by rules that read its title, its abstract and its classification codes. A theme needs the wording in the title, a class, or wording the abstract returns to; one passing word is not enough. Themes say what a filing is about. They are not a reading of its claims, and the claims are what define legal scope.
Claims. Where an editor has read a family’s claims and written what they appear to address, that note is marked as an editorial interpretation and appears only after review. No claim interpretation is generated and published automatically, and none states what a patent covers in law. Conclusions about competition or freedom to operate are not drawn at all.
Status. A family is shown as granted when an office published a grant for one of its members, read from the kind of publication, and only for offices where that reading is unambiguous. Granted does not mean in force. Events offices recorded, such as lapses, withdrawals and changes of owner, are shown in the offices’ own words on a family’s page where they have been read, and are not interpreted.
Limits. Applications are published about eighteen months after they are first filed, so the latest 3 priority years are incomplete and are drawn apart in every chart. Discovery is targeted and will miss families that use neither the field’s classes nor its wording. Utility models and filings made only in one country are less completely indexed than international ones. Names are matched conservatively, so a portfolio can be undercounted where an organisation files under a name not yet known here. Patent counts measure filing activity. They are not a measure of technical quality, of the value of a portfolio or of commercial success.
08 · Forecasts
Speculation is labelled as speculation
Forward-looking statements are sorted into four kinds: an observed trajectory, a plausible next milestone, a necessary breakthrough and a key uncertainty. Only the first describes something that has happened.
Forecasts carry a date. When the Outlook is revised, earlier statements will be kept and compared with what occurred, so that readers can judge how well we forecast.
Capital coverage is descriptive. We do not recommend, rank or score companies as investments, and the funding charts are sums of a stated sample of announcements, not estimates of the market.